Stocklytics Platform
Asset logo for symbol SLN
Silence Therapeutics plc
SLN50
$6.88arrow_drop_up7.64%$0.48
Asset logo for symbol SLN
SLN50

$6.88

arrow_drop_up7.64%

Performance History

Chart placeholder
Key Stats
Open$6.28
Prev. Close$6.34
EPS-1.71
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range6.31
7.09
52 Week Range5.84
27.72
Ratios
EPS-1.71

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Silence Therapeutics plc (SLN)

Silence Therapeutics plc, also known by its stock ticker symbol SLN, is a leading biotechnology company specializing in RNA interference (RNAi) therapeutics. The company is dedicated to developing innovative therapies that can target and silence disease-causing genes, offering a potential breakthrough in the treatment of various diseases. With a strong focus on precision medicine, Silence Therapeutics aims to deliver customized RNAi therapeutics to patients suffering from conditions such as cancer, cardiovascular diseases, and genetic disorders.
As of the latest available data, the stock price history of Silence Therapeutics plc (SLN) has shown significant fluctuations over the years. Investors should note that stock prices can be influenced by various factors, including market conditions, company performance, and investor sentiment. It is advisable to consult a financial expert or conduct thorough research before making investment decisions related to SLN stock.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Craig A. Tooman M.B.A., MBA
Headquarters
London
Employees
122
Exchange
NASDAQ
add Silence Therapeutics plc to watchlist

Keep an eye on Silence Therapeutics plc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Silence Therapeutics plc's (SLN) price per share?

The current price per share for Silence Therapeutics plc (SLN) is $6.88. The stock has seen a price change of $0.49 recently, indicating a 7.65% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Silence Therapeutics plc (SLN)?

For Silence Therapeutics plc (SLN), the 52-week high is $27.72, which is 302.91% from the current price. The 52-week low is $5.85, the current price is 17.63% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Silence Therapeutics plc (SLN) a growth stock?

Silence Therapeutics plc (SLN) has shown an average price growth of -4.38% over the past three years. It has received a score of 13 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Silence Therapeutics plc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Silence Therapeutics plc (SLN) stock price performance year to date (YTD)?

As of the latest data, Silence Therapeutics plc (SLN) has a year-to-date price change of -62.91%. Over the past month, the stock has experienced a price change of -10.42%. Over the last three months, the change has been -61.78%. Over the past six months, the figure is -64.99%.
help

Is Silence Therapeutics plc (SLN) a profitable company?

Silence Therapeutics plc (SLN) has a net income of -$50.31M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 59.34% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.06K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $25.38M, with a revenue growth rate of 44.99%, providing insight into the company's sales performance and growth. The gross profit is $15.06M. Operating income is noted at -$49.6M. Furthermore, the EBITDA is -$60.67M.
help

What is the market capitalization of Silence Therapeutics plc (SLN)?

Silence Therapeutics plc (SLN) has a market capitalization of $324.84M. The average daily trading volume is 6.82, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level